ETF overview
The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund (ETF) designed with a clear purpose: to accurately reflect the price movements and income generated by the NYSE Arca Biotechnology Index. Its core objective is to closely match the performance of this benchmark index, before accounting for the fund's operational fees and expenses.
Fund facts
- Expense ratio
- 0.55%
- Fund assets
- 2.99B USD (all share classes)
- Issuer
- First Trust
- Inception date
- Jun 19, 2006
- Number of holdings
- 30
Breakdown
Holdings (30)
| Name | Ticker | Weight |
|---|---|---|
| Halozyme Therapeutics, Inc. | HALO | 3.71% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.56% |
| Amgen Inc. | AMGN | 3.50% |
| BeOne Medicines Ltd. (ADR) | ONC | 3.50% |
| Exelixis, Inc. | EXEL | 3.49% |
| Gilead Sciences, Inc. | GILD | 3.47% |
| ADMA Biologics, Inc. | ADMA | 3.46% |
| Biogen Inc. | BIIB | 3.46% |
| NeoGenomics, Inc. | NEO | 3.42% |
| Alkermes Plc | ALKS | 3.41% |
| and 17 more | ||
Similar ETFs
- Invesco Biotechnology & Genome ETFPBE · Overlap 48% · Expense ratio 0.59%
- iShares Biotechnology ETFIBB · Overlap 44% · Expense ratio 0.44%
- VanEck Biotech ETFBBH · Overlap 41% · Expense ratio 0.35%
- First Trust Nasdaq Pharmaceuticals ETFFTXH · Overlap 35% · Expense ratio 0.60%
- Invesco Nasdaq Biotechnology ETFIBBQ · Overlap 33% · Expense ratio 0.19%
- Invesco NASDAQ Biotech UCITS ETFSBIO.L · Overlap 33% · Expense ratio 0.40%
- iShares Nasdaq US Biotechnology UCITS ETFBTEC.L · Overlap 33% · Expense ratio 0.35%
- MiraeAsset TIGER NASDAQ BIO ETF203780.KS · Overlap 33% · Expense ratio 0.30%
Overlap is the share of assets the two funds hold in common.
Historical returns do not guarantee future returns. This is not investment advice.
First Trust NYSE Arca Biotechnology Index Fund (FBT)
- Expense ratio
- 0.55%
- Fund assets
- 2.99B USD (all share classes)
- Issuer
- First Trust
- Inception date
- Jun 19, 2006
- Number of holdings
- 30
| Name | Ticker | Weight |
|---|---|---|
| Halozyme Therapeutics, Inc. | HALO | 3.71% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.56% |
| Amgen Inc. | AMGN | 3.50% |
| BeOne Medicines Ltd. (ADR) | ONC | 3.50% |
| Exelixis, Inc. | EXEL | 3.49% |
| Gilead Sciences, Inc. | GILD | 3.47% |
| ADMA Biologics, Inc. | ADMA | 3.46% |
| Biogen Inc. | BIIB | 3.46% |
| NeoGenomics, Inc. | NEO | 3.42% |
| Alkermes Plc | ALKS | 3.41% |
| and 17 more | ||
The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund (ETF) designed with a clear purpose: to accurately reflect the price movements and income generated by the NYSE Arca Biotechnology Index. Its core objective is to closely match the performance of this benchmark index, before accounting for the fund's operational fees and expenses.
- Invesco Biotechnology & Genome ETFPBE · Overlap 48% · Expense ratio 0.59%
- iShares Biotechnology ETFIBB · Overlap 44% · Expense ratio 0.44%
- VanEck Biotech ETFBBH · Overlap 41% · Expense ratio 0.35%
- First Trust Nasdaq Pharmaceuticals ETFFTXH · Overlap 35% · Expense ratio 0.60%
- Invesco Nasdaq Biotechnology ETFIBBQ · Overlap 33% · Expense ratio 0.19%
- Invesco NASDAQ Biotech UCITS ETFSBIO.L · Overlap 33% · Expense ratio 0.40%
- iShares Nasdaq US Biotechnology UCITS ETFBTEC.L · Overlap 33% · Expense ratio 0.35%
- MiraeAsset TIGER NASDAQ BIO ETF203780.KS · Overlap 33% · Expense ratio 0.30%
Overlap is the share of assets the two funds hold in common.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free